TY - JOUR
T1 - Immunotherapy in nonmuscle invasive bladder cancer
T2 - Current and emerging treatments
AU - Gupta, Mohit
AU - Kates, Max
AU - Bivalacqua, Trinity J.
N1 - Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Purpose of reviewThere is a significant unmet need for efficacious second-line treatment options for patients who have failed bacillus Calmette-Guerin (BCG) therapy for nonmuscle invasive urothelial carcinoma (NMIBC). Recent advances in our understanding of systemic immunotherapy have transformed the management of advanced urothelial carcinoma and have led to the development of multiple novel agents. Using this insight, these agents are now being investigated for use in NMIBC.Recent findingsAlthough BCG has been used to treat high-risk NMIBC for decades, new applications of immunotherapy include the use of exogenous cytokines to boost immune response, vaccines to activate the immune system against specific tumor-associated antigens, intravesical agents that cause generalized local inflammation, and targeted antibodies against proteins on the surface of immune checkpoint inhibitors. Although most of these agents are still being investigated in clinical trials and are not yet considered standard of care, they hold significant promise in the treatment of patients with high-risk NMIBC.SummaryThe use of immunotherapy has significantly improved survival outcomes in advanced urothelial carcinoma. Based on rapid advances in our understanding of the immune system and tumor biology, these agents are also poised to alter the therapeutic landscape for NMIBC dramatically as clinical trials are completed.
AB - Purpose of reviewThere is a significant unmet need for efficacious second-line treatment options for patients who have failed bacillus Calmette-Guerin (BCG) therapy for nonmuscle invasive urothelial carcinoma (NMIBC). Recent advances in our understanding of systemic immunotherapy have transformed the management of advanced urothelial carcinoma and have led to the development of multiple novel agents. Using this insight, these agents are now being investigated for use in NMIBC.Recent findingsAlthough BCG has been used to treat high-risk NMIBC for decades, new applications of immunotherapy include the use of exogenous cytokines to boost immune response, vaccines to activate the immune system against specific tumor-associated antigens, intravesical agents that cause generalized local inflammation, and targeted antibodies against proteins on the surface of immune checkpoint inhibitors. Although most of these agents are still being investigated in clinical trials and are not yet considered standard of care, they hold significant promise in the treatment of patients with high-risk NMIBC.SummaryThe use of immunotherapy has significantly improved survival outcomes in advanced urothelial carcinoma. Based on rapid advances in our understanding of the immune system and tumor biology, these agents are also poised to alter the therapeutic landscape for NMIBC dramatically as clinical trials are completed.
KW - bacillus Calmette-Guerin
KW - immune checkpoint inhibitors
KW - immunotherapy
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85064886081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064886081&partnerID=8YFLogxK
U2 - 10.1097/CCO.0000000000000533
DO - 10.1097/CCO.0000000000000533
M3 - Review article
C2 - 30893148
AN - SCOPUS:85064886081
SN - 1040-8746
VL - 31
SP - 183
EP - 187
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 3
ER -